US Patent

US11957681 — Liquid dosage forms of Imatinib

Formulation · Assigned to Shorla Pharma Ltd · Expires 2040-04-27 · 14y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects liquid dosage forms of Imatinib mesylate that consistently administer the correct dose of the drug.

USPTO Abstract

Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.

Drugs covered by this patent

Patent Metadata

Patent number
US11957681
Jurisdiction
US
Classification
Formulation
Expires
2040-04-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Shorla Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.